Lowenstein advised Hildred Capital Management and Crown Laboratories on the deal, while Gibson, Dunn & Crutcher advised StriVectin and L Catterton.
Hildred Capital Management (Hildred) and Crown Laboratories (Crown), a leading, fully integrated, global skincare company and Hildred portfolio company, and L Catterton, the largest global consumer-focused private equity firm, have closed a transaction pursuant to which Crown acquired StriVectin, a broad range of award-winning skincare solutions for all skin types, tones, and ages. Other equity sponsors in Crown include Greenspring Associates and Montreux Growth Partners.
StriVectin’s products have become part of Crown’s new Premium Skincare Division and will operate as a wholly-owned subsidiary of Crown. The acquisition strengthens Crown’s overall skincare product portfolio, which includes Crown Aesthetics, maker of SkinPen®, the first FDA-cleared microneedling device, as well as Crown Therapeutics, maker of PanOxyl® (the No. 1 acne wash) Sarna® (the No. 1 dermatologist-recommended topical anti-itch brand and recipient of the National Seal of Acceptance from the National Eczema Association), and Blue Lizard® Australian Sunscreen, the No. 1 pediatrician recommended mineral-based sunscreen brand.
Terms of the transaction were not disclosed.
Crown, a privately held, fully integrated global skincare company, is committed to developing and providing a diverse portfolio of aesthetic, premium beauty, and therapeutic skincare products that improve the quality of life for its customers. Crown has been listed on the Inc. 5000 Fastest Growing Privately Held Companies List for eight years and has expanded its distribution to over 38 countries.
Hildred is a New York-based private equity investment firm that pursues growth equity investments in lower middle market health care companies with leading products, technologies, and services.
Hayfin Capital Management, LLP provided debt financing in connection with the transaction. Moelis & Company LLC acted as exclusive financial advisor to StriVectin.
The Lowenstein deal team included Sam E. Khan (Picture), Mitchell McDonald, Danielle M. Falzone, Latoya Bethune, Diana Kim, Emily B. Sklar, and Megan Williams (Mergers & Acquisitions); James C. Shehan (FDA Regulatory); Nicholas G. Mehler, Matthew P. Hintz, Jenna-Marie Tracy, and Oluwaseyi Amorin (The Tech Group); Theodore C. Sica, Fran Skoller, and Michael A. Buxbaum (Debt Financing); Brian A. Silikovitz and Kristin V. Taylor (Tax); Megan Monson and Taryn E. Cannataro (Employee Benefits & Executive Compensation); Amy C. Schwind (Employment Counseling & Litigation); Alex H. Rosenthal (Real Estate); Norman W. Spindel and Mark S. Heinzelmann (Environmental Law & Litigation); Manali Joglekar (Privacy & Cybersecurity); Eric Jesse (Insurance Recovery); Jeffrey M. Shapiro and Sydney J. Kaplan (Antitrust/Competition); Edward S. Nadel and Kenneth D. Kirschenbaum (Investment Management); and Matthew M. Oliver (Business Litigation).
Involved fees earner: Matthew Oliver – Latham & Watkins; Oluwaseyi Amorin – Lowenstein Sandler; Latoya Bethune – Lowenstein Sandler; Michael Buxbaum – Lowenstein Sandler; Taryn Cannataro – Lowenstein Sandler; Danielle Falzone – Lowenstein Sandler; Mark Heinzelmann – Lowenstein Sandler; Matthew Hintz – Lowenstein Sandler; Eric Jesse – Lowenstein Sandler; Manali Joglekar – Lowenstein Sandler; Sydney Kaplan – Lowenstein Sandler; Sam Khan – Lowenstein Sandler; Diana Kim – Lowenstein Sandler; Kenneth Kirschenbaum – Lowenstein Sandler; Mitchell McDonald – Lowenstein Sandler; Nicholas Mehler – Lowenstein Sandler; Megan Monson – Lowenstein Sandler; Edward Nadel – Lowenstein Sandler; Alex Rosenthal – Lowenstein Sandler; Amy Schwind – Lowenstein Sandler; Jeffrey Shapiro – Lowenstein Sandler; James Shehan – Lowenstein Sandler; Theodore Sica – Lowenstein Sandler; Brian Silikovitz – Lowenstein Sandler; Emily Sklar – Lowenstein Sandler; Fran Skoller – Lowenstein Sandler; Norman Spindel – Lowenstein Sandler; Kristin Taylor – Lowenstein Sandler; Jenna-Marie Tracy – Lowenstein Sandler; Megan Williams – Lowenstein Sandler;